JAMA dermatology最新文献

{"title":"Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events.","authors":"Maxime Raby, Frederic Balusson, Emmanuel Oger, Marion Gundelwein, Alain Dupuy, Florence Poizeau","doi":"10.1001/jamadermatol.2025.2972","DOIUrl":"10.1001/jamadermatol.2025.2972","url":null,"abstract":"<p><strong>Importance: </strong>The cardiovascular impact of biologics used in psoriasis is not fully understood. Several studies have suggested that the inhibition of the T-helper 17 cell pathway could lead to the destabilization of atherosclerotic plaques, leading to major adverse cardiovascular events (MACEs).</p><p><strong>Objective: </strong>To assess whether the initiation of interleukin (IL)-17(R)A inhibitors triggers MACEs.</p><p><strong>Design, setting, and participants: </strong>In this case-time-control study using the French National Health Insurance database, all individuals who received IL-17(R)A inhibitors (secukinumab, ixekizumab, and brodalumab) from 2016 to 2021, were included and classified according to their cardiovascular risk level. The risk period was defined as the 6 months before the MACE, and the reference period as the 6 months before the risk period. The same design for patients who received tumor necrosis factor (TNF)-α inhibitors (adalimumab or etanercept) for similar indications (psoriasis, psoriatic arthritis, ankylosing spondylitis, or juvenile arthritis), as an active comparator. The data analysis was conducted between April 2023 and August 2024.</p><p><strong>Exposure: </strong>The initiation of the biologic was screened in both periods.</p><p><strong>Main outcomes and measures: </strong>The odds ratios (ORs) for the risk of MACEs were assessed following the initiation of IL-17(R)A inhibitors and TNF-α inhibitors independently. Subsequently, the OR for the risk of MACE associated with IL-17(R)A inhibitors was estimated using TNF-α inhibitors as the comparator.</p><p><strong>Results: </strong>Among the 34 241 individuals who received an IL-17(R)A inhibitor, 381 MACEs were analyzed, including 176 acute coronary syndromes and 84 ischemic strokes in the main analysis. Initiation of IL-17(R)A inhibitors was not significantly associated with MACEs (OR, 1.25 [95% CI, 0.75-2.08] vs TNF-α inhibitor initiation and MACEs: OR, 0.90 [95% CI, 0.65-1.24]). Overall, the initiation of an IL-17(R)A inhibitor was not significantly associated with MACEs in the following 6 months, using TNF-α inhibitor as a comparator (OR, 1.40 [95% CI, 0.77-2.54]), regardless of the individual cardiovascular risk (P for homogeneity = .29). The definition of MACE was broadened in a first sensitivity analysis, and the risk period was shortened to 3 months in a second sensitivity analysis. The results did not change.</p><p><strong>Conclusions: </strong>In this case-time-control study based on a national insurance database, there was no evidence of a significant association between MACEs and the initiation of IL-17(R)A inhibitors, regardless of the individual cardiovascular risk of the patient. However, a modest risk increase cannot be entirely excluded.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12409656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144954782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-Throughput Sequencing and Estimated Relapse Risk in Patients With Sézary Syndrome.","authors":"Jeffrey D Weiner, David M Weiner, Bernice Benoit, Jessica E Teague, Rachael A Clark, Alain H Rook","doi":"10.1001/jamadermatol.2025.3054","DOIUrl":"10.1001/jamadermatol.2025.3054","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12409640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144954846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypertrophic Lichen Planus.","authors":"Ruimiao Wu, Yu Hu","doi":"10.1001/jamadermatol.2025.2995","DOIUrl":"https://doi.org/10.1001/jamadermatol.2025.2995","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144954844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paradoxical Enhancement of Cancer Immunotherapy With JAK Inhibitors.","authors":"Jonathan J Park, Jennifer N Choi","doi":"10.1001/jamadermatol.2025.3059","DOIUrl":"https://doi.org/10.1001/jamadermatol.2025.3059","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144954868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Incident Nevus-Associated vs De Novo Invasive Melanoma.","authors":"Catherine M Olsen, Maja M Shalit, Nirmala Pandeya, Rachel E Neale, G J M Shanika R Jayasinghe, Matthew H Law, David C Whiteman","doi":"10.1001/jamadermatol.2025.2004","DOIUrl":"10.1001/jamadermatol.2025.2004","url":null,"abstract":"<p><strong>Importance: </strong>No prospective epidemiologic studies have investigated genetic vs environmental factors on the risks of nevus-associated melanoma (NAM) and de novo melanoma.</p><p><strong>Objective: </strong>To determine whether the risk factor profile differs for nevus-associated and de novo invasive melanoma, and whether the associations differ according to sex.</p><p><strong>Design, setting, and participants: </strong>This population-based prospective cohort study (the QSkin Study) conducted in Queensland, Australia, included participants aged 40 to 69 years at baseline. Participants were recruited in 2011 and followed up until December 2022. All analyses were conducted between October 2024 and January 2025.</p><p><strong>Exposures: </strong>Self-reported information from the baseline survey on phenotypic factors (hair color, tanning ability, nevus density, family history), sun exposure-related factors (sunburns, history of skin cancers and actinic lesions), and polygenic risk scores for melanoma and nevus development was collected.</p><p><strong>Main outcome and measures: </strong>The primary outcome was incident invasive melanoma (nevus-associated and de novo).</p><p><strong>Results: </strong>A total of 17 752 males and 21 049 females were included and 859 were analyzed. During a median (IQR) follow-up of 11.4 (11.2-11.7) years, 209 participants developed an invasive nevus-associated melanoma (129 in males and 80 in females) and 650 developed an invasive de novo melanoma (362 in males and 288 in females). Many of the known phenotypic and sun exposure-related risk factors for melanoma were similarly associated with nevus-associated and de novo melanoma, but high nevus density and high genetic propensity for melanoma development had significantly higher hazard ratios (HRs) for NAM than de novo melanoma (HR for many moles vs no moles, 6.86 [95% CI, 3.82-12.33] vs 3.21 [95% CI, 2.23-4.63]; P = .001; HR for melanoma polygenic risk score tertile 3 vs tertile 1, 6.46 [95% CI, 3.42-12.20) vs 2.98 [95% CI, 2.21-4.02]; P = .006). No significant differences in the risk factor profile for NAM were found for sex, but the HR for older age was significantly higher among males with de novo melanoma than in females. The site distribution of NAM differed for males and females, occurring mostly commonly on the trunk in males and on the limbs in females.</p><p><strong>Conclusions and relevance: </strong>Results of this study identified distinct risk factor profiles for NAM and de novo melanomas, particularly polygenic risk and nevus propensity. Males and females tended to develop NAM on different body sites, which may have implications for early detection strategies.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"941-949"},"PeriodicalIF":11.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12242815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lupus Vulgaris.","authors":"Chuan-Peng Wang, Jia Zhou, Jun Li","doi":"10.1001/jamadermatol.2025.1799","DOIUrl":"10.1001/jamadermatol.2025.1799","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"970-971"},"PeriodicalIF":11.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subclinical Synovitis Among Patients With Psoriasis Without Musculoskeletal Involvement: A Systematic Review and Meta-Analysis.","authors":"Shanti Mehta, Grace Xiong, Dea Metko, Parsa Abdi, Eric McMullen, Raed Alhusayen","doi":"10.1001/jamadermatol.2025.2281","DOIUrl":"10.1001/jamadermatol.2025.2281","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Psoriasis affects up to 3% of the population, with 30% of patients with psoriasis developing psoriatic arthritis (PsA), yet the transition between psoriasis and PsA has yet to be fully understood. Subclinical synovitis is a hallmark of PsA and is thought to precede psoriatic arthritis; its detection among patients with psoriasis without musculoskeletal (MSK) involvement through medical imaging modalities could offer valuable insights into the transition from psoriasis to PsA.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To evaluate the prevalence of synovitis on ultrasonograms and magnetic resonance imaging (MRI) among patients with psoriasis without MSK involvement compared with healthy controls and patients with PsA.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Data sources: &lt;/strong&gt;A comprehensive literature search was conducted in MEDLINE, Embase, Scopus, and Web of Science from inception to October 2024 using keywords related to psoriasis, synovitis, and medical imaging. A PROSPERO protocol was registered (CRD42024571308).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Study selection: &lt;/strong&gt;Studies were eligible if they included patients with psoriasis without MSK involvement and assessed synovitis using imaging. Two reviewers independently screened studies and extracted data. Discrepancies were resolved by consensus. Twelve of 5132 initially identified studies met inclusion criteria.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Data extraction and synthesis: &lt;/strong&gt;Data were extracted per PRISMA guidelines. Risk of bias was assessed using the Newcastle-Ottawa Scale. A random-effects model was used to pool risk ratios (RRs) for synovitis prevalence across comparison groups. Heterogeneity was assessed using the I2 statistic.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;The primary outcome was the presence of imaging-detected synovitis among patients with psoriasis without MSK involvement compared with healthy controls and patients with PsA.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Twelve studies (N = 2606 patients) were included comprising 1593 patients with psoriasis (mean [SD] age, 46.4 [7.5] years; 982 men [61.6%]), 327 patients with PsA (mean [SD] age, 50.2 [7.1] years; 210 men [64.2%]), and 686 healthy controls (mean [SD] age, 45.7 [6.9] years; 281 of 576 men [48.8%]). Synovitis was 2.5 times more likely among patients with psoriasis than controls (RR, 2.55; 95% CI, 1.18-5.52). Detection rates were higher with MRI (RR, 6.40; 95% CI, 1.87-21.95) than ultrasonography (RR, 2.50; 95% CI, 1.10-5.67). Synovitis was more frequent among patients with PsA than those with psoriasis, but the difference was not statistically significant (RR, 0.50; 95% CI, 0.13-1.87).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;This systematic review and meta-analysis found that subclinical synovitis is significantly more prevalent among patients with psoriasis without MSK involvement compared with healthy controls. This finding suggests that imaging may aid in identifying individuals at risk for progression to psoriatic arthriti","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"966-969"},"PeriodicalIF":11.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Error in Text.","authors":"","doi":"10.1001/jamadermatol.2025.3597","DOIUrl":"10.1001/jamadermatol.2025.3597","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":"161 9","pages":"985"},"PeriodicalIF":11.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145075284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial.","authors":"Amy McMichael, Mona Shahriari, Linda Stein Gold, Theodore Alkousakis, Olivia Choi, Tina Bhutani, Adrian O Rodriguez, Stephen K Tyring, Daphne Chan, Katelyn Rowland, Lorne Albrecht, Charles Lynde, Geeta Yadav, Jensen Yeung, Laura Park-Wyllie, Tony Ma, Jenny Jeyarajah, Long-Long Gao, Stacy Smith, Angela Y Moore, Neelam Vashi, Chesahna Kindred, Pearl Grimes, Seemal R Desai, Susan C Taylor, Andrew Alexis","doi":"10.1001/jamadermatol.2025.1849","DOIUrl":"10.1001/jamadermatol.2025.1849","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Varying hair textures and hair care practices contribute to nuances in clinical presentation and management of scalp psoriasis across diverse patient populations. Cohort B of the VISIBLE trial enrolled participants with moderate to severe scalp psoriasis and skin of color, across the skin-tone spectrum.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To evaluate efficacy, quality of life, and adverse event outcomes of guselkumab, 100 mg, among participants with moderate to severe scalp psoriasis and skin of color over 48 weeks.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This ongoing phase 3b, randomized clinical trial at 45 sites in the US and Canada enrolled adults with skin of color and moderate to severe scalp psoriasis (scalp surface area [SSA] ≥30%; Psoriasis Scalp Severity Index [PSSI] ≥12; scalp-specific Investigator's Global Assessment [ss-IGA] score ≥3; ≥1 nonscalp plaque). Data were collected from September 2022 to June 2024.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interventions: &lt;/strong&gt;Randomized participants (3:1) received guselkumab, 100 mg, at weeks 0, 4, and every 8 weeks, or placebo at weeks 0, 4, and 12, then guselkumab at weeks 16, 20, and every 8 weeks.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Coprimary end points were ss-IGA score of 0 or 1 (ss-IGA 0/1) and 90% or greater improvement in PSSI (PSSI 90) at week 16 (guselkumab vs placebo). Major secondary end points included ss-IGA 0 (complete scalp clearance), PSSI 100, percentage changes from baseline in PSSI and SSA, changes from baseline in Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD) symptoms score, and 4-point or greater reduction in Scalp Itch Numeric Rating Scale (NRS) score.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Of 108 participants (81 randomized to guselkumab; 27 randomized to placebo), 100 (92.6%) completed 48 weeks of treatment. The mean (SD) age overall was 42.5 (13.6) years, and 58 participants (56.9%) were male. At the week 16 primary end point, in the guselkumab (n = 76) vs placebo (n = 26) groups, respectively, response rates were as follows: ss-IGA 0/1, 68.4% (n = 52) vs 11.5% (n = 3) (P &lt; .001); PSSI 90, 65.8% (n = 50) vs 3.8% (n = 1) (P &lt; .001); ss-IGA 0, 57.9% (n = 44) vs 3.8% (n = 1) (P &lt; .001); PSSI 100, 59.2% (n = 45) vs 3.8% (n = 1) (P &lt; .001); 4-point or greater reduction in Scalp Itch NRS score (in those with a baseline score of at least 4), 69.4% (n = 50 of 72) vs 24.0% (n = 6 of 25) (P &lt; .001). Guselkumab efficacy increased and was maintained through week 48, when guselkumab-randomized participants achieved mean (SD) percentage improvements in PSSI and SSA of 94.6% (12.2%) and 94.8% (16.2%), respectively, and 51 (67.1%) achieved ss-IGA 0. DLQI and PSSD symptoms score least-squares mean changes were -9.7 (95% CI, -11.1 to -8.2) vs -2.2 (95% CI, -4.8 to 0.4) (P &lt; .001) and -44.8 (95% CI, -50.6 to -39.1) vs -8.3 (95% CI, -18.4 to 1.9) (P &lt; .001), respectively, with sustained improvements through week 48","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"912-922"},"PeriodicalIF":11.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa: A Living Systematic Review and Network Meta-Analysis.","authors":"Amit Garg, Erica Cohn, Bria Midgette, Kelly Frasier, Andrew Strunk","doi":"10.1001/jamadermatol.2025.1976","DOIUrl":"10.1001/jamadermatol.2025.1976","url":null,"abstract":"<p><strong>Importance: </strong>There is limited comparative information on regulatory approved and pipeline treatments in hidradenitis suppurativa (HS).</p><p><strong>Objective: </strong>To compare efficacy, safety, and tolerability of treatments for moderate to severe HS.</p><p><strong>Data sources: </strong>MEDLINE, Embase, ClinicalTrials.gov, and Cochrane Central Register of Controlled Trials were searched from inception to June 28, 2024.</p><p><strong>Study selection: </strong>Phase 2 and 3 randomized clinical trials of medical interventions (cytokine inhibitors, small molecule inhibitors, cell inhibitors, and other novel immune or inflammatory modifiers) for adults with moderate to severe HS having primary efficacy assessments between 12 and 16 weeks.</p><p><strong>Data extraction and synthesis: </strong>Data extraction and risk of bias assessments were performed independently by 2 reviewers. Efficacy outcomes were analyzed using random-effects network meta-analysis. Safety and tolerability outcomes were analyzed using pairwise fixed-effect meta-analyses vs placebo. Data analysis was performed between August 22, 2024, and April 7, 2025.</p><p><strong>Main outcomes and measures: </strong>Primary efficacy, safety, and tolerability outcomes were Hidradenitis Suppurativa Clinical Response (HiSCR)-50, occurrence of serious adverse events (SAEs), and treatment discontinuation due to adverse events, respectively. HiSCR-75 was a secondary efficacy outcome.</p><p><strong>Results: </strong>Of 26 eligible trials, 25 had available HiSCR-50 data, including 5767 total patients and 39 unique treatments. Compared with placebo, the following treatments were associated with significantly higher HiSCR-50 response rates: sonelokimab, 120 mg, every 4 weeks; lutikizumab, 300 mg, every 2 weeks; adalimumab, 40 mg, once per week; sonelokimab, 240 mg, every 2 weeks; bimekizumab, 320 mg, every 2 weeks; povorcitinib, 15 mg, once per day; bimekizumab, 320 mg, every 4 weeks; secukinumab, 300 mg, every 4 weeks; and secukinumab, 300 mg, every 2 weeks. Most differences between adalimumab, 40 mg, once per week, and other targeted treatments were not statistically significant. The percentage of patients experiencing SAEs ranged from 0% to 10% in the placebo groups, 0% to 8% in the adalimumab (40 mg, once per week) groups, and 0% to 6% in the other active treatment groups. The percentage of patients discontinuing treatment due to adverse events ranged from 0% to 10% in the placebo groups, 0% to 4% in the adalimumab (40 mg, once per week) groups, and 0% to 15% (ropsacitinib) in the other active treatment groups.</p><p><strong>Conclusions and relevance: </strong>This network meta-analysis provides evidence for the comparative efficacy and safety of currently approved and pipeline medications for moderate to severe HS in the absence of head-to-head trials.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"931-940"},"PeriodicalIF":11.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}